Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr;28(4):400-4.
doi: 10.1089/aid.2011.0240. Epub 2011 Sep 27.

Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide

Morgane Rolland  1 , Peter Gilbert
Affiliations

Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide

Morgane Rolland et al. AIDS Res Hum Retroviruses. 2012 Apr.

Abstract

Since the RV144 vaccine combination showed efficacy in a Phase III trial, it provides an opportunity to generate hypotheses about the immune responses necessary for protection against HIV-1 infection, and these results could help devise vaccine candidates with higher efficacy. Here we describe how researchers can determine the correlates of immune protection for an HIV/AIDS vaccine, particularly in the context of the RV144 trial, and we discuss the terminology used to describe correlates and surrogates.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Power to detect a normally distributed correlate of risk in RV144.
See this image and copyright information in PMC

Similar articles

  • Support for the RV144 HIV vaccine trial.
    Belshe R, Franchini G, Girard MP, Gotch F, Kaleebu P, Marthas ML, McChesney MB, McCullough R, Mhalu F, Salmon-Ceron D, Sekaly RP, van Rompay K, Verrier B, Wahren B, Weissenbacher M. Belshe R, et al. Science. 2004 Jul 9;305(5681):177-80; author reply 177-80. doi: 10.1126/science.305.5681.177b. Science. 2004. PMID: 15247455 No abstract available.
  • Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW, Allen M, Malahleha M, Mngadi K, Daniels B, Innes C, Bentley C, Frahm N, Morris DE, Morris L, Mkhize NN, Montefiori DC, Sarzotti-Kelsoe M, Grant S, Yu C, Mehra VL, Pensiero MN, Phogat S, DiazGranados CA, Barnett SW, Kanesa-Thasan N, Koutsoukos M, Michael NL, Robb ML, Kublin JG, Gilbert PB, Corey L, Gray GE, McElrath MJ; HVTN 100 Protocol Team. Bekker LG, et al. Lancet HIV. 2018 Jul;5(7):e366-e378. doi: 10.1016/S2352-3018(18)30071-7. Epub 2018 Jun 18. Lancet HIV. 2018. PMID: 29898870 Free PMC article. Clinical Trial.
  • Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.
    Gartland AJ, Li S, McNevin J, Tomaras GD, Gottardo R, Janes H, Fong Y, Morris D, Geraghty DE, Kijak GH, Edlefsen PT, Frahm N, Larsen BB, Tovanabutra S, Sanders-Buell E, deCamp AC, Magaret CA, Ahmed H, Goodridge JP, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, deSouza MS, Nitayaphan S, Rerks-Ngarm S, Robb ML, Sidney J, Sette A, Zolla-Pazner S, Montefiori D, McElrath MJ, Mullins JI, Kim JH, Gilbert PB, Hertz T. Gartland AJ, et al. J Virol. 2014 Aug;88(15):8242-55. doi: 10.1128/JVI.01164-14. Epub 2014 May 14. J Virol. 2014. PMID: 24829343 Free PMC article. Clinical Trial.
  • Prospects for a globally effective HIV-1 vaccine.
    Excler JL, Robb ML, Kim JH. Excler JL, et al. Vaccine. 2015 Nov 27;33 Suppl 4:D4-12. doi: 10.1016/j.vaccine.2015.03.059. Epub 2015 Jun 20. Vaccine. 2015. PMID: 26100921 Review.
  • HIV Vaccine Efficacy Trials: RV144 and Beyond.
    Heger E, Schuetz A, Vasan S. Heger E, et al. Adv Exp Med Biol. 2018;1075:3-30. doi: 10.1007/978-981-13-0484-2_1. Adv Exp Med Biol. 2018. PMID: 30030787 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Prentice RL. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med. 1989;8(4):431–440. - PubMed
    1. Frangakis CE. Rubin DB. Principal stratification in causal inference. Biometrics. 2002;58(1):21–29. - PMC - PubMed
    1. Qin L. Gilbert PB, et al. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis. 2007;196(9):1304–1312. - PubMed
    1. Plotkin SA. Vaccines: Correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47(3):401–409. - PubMed
    1. Borgan O., et al. Exposure stratified case-cohort designs. Lifetime Data Anal. 2000;6(1):39–58. - PubMed

Publication types